A review of the use of modafinil for attention-deficit hyperactivity disorder

  title={A review of the use of modafinil for attention-deficit hyperactivity disorder},
  author={Danielle Turner},
  journal={Expert Review of Neurotherapeutics},
  pages={455 - 468}
  • Danielle Turner
  • Published 1 April 2006
  • Psychology, Medicine
  • Expert Review of Neurotherapeutics
Modafinil (Provigil™) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. In particular, three large, drug-company sponsored trials of a film-coated formulation of modafinil (modafinil-ADHD; Sparlon™) in children and adolescents with ADHD demonstrated consistent improvements in ADHD symptoms compared with placebo. Mean reductions in symptom ratings (measured… 

The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders

Positive trends in several result measures suggest that medications that improve cognitive function, like MOD or R-MOD, may be beneficial for the treatment of substance use disorders in certain patient populations.

Utilidad de Modafilino en trastorno por déficit de atención en hiperactividad

The most common adverse effects were headache, insomnia and decreased appetite, and new trials comparing effectiveness of modafinilo and stimulants drugs in ADHD are necessaries.

Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers

The current data suggest that the cognitive effects of modafinil on performance accuracy and latency are dissociable in terms of their neurochemical mechanisms.

Current issues and trends in the diagnosis and treatment of adults with ADHD

The prevalence of adults with ADHD is reviewed, followed by a discussion of the neurobiological and genetic underpinnings of the disorder.

Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence

  • M. Schlander
  • Medicine, Political Science
    Child and adolescent psychiatry and mental health
  • 2007
A more than six-fold increase of pharmaceutical spending for children and adolescents is predicted over the decade from 2002 to 2012, from the perspectives of both the NHS in England and the GKV in Germany.

Pharmacological strategies for enhancing cognition in schizophrenia.

  • D. Barch
  • Psychology, Medicine
    Current topics in behavioral neurosciences
  • 2010
Although many of the single-dose and open-label studies have suggested positive cognitive effects from a range of agents, few of the larger-scale double-blind studies have generated positive results, and the current state of results may reflect the need to identify alternative molecular mechanisms for enhancing cognition in schizophrenia or theneed to reconceptualize the ways in which pharmacological agents may improve cognition in this illness.



Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.

Modafinil may be a useful once-daily treatment for children with ADHD and a double-blind, placebo-controlled design is needed.

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults.

  • F. TaylorJ. Russo
  • Psychology, Medicine
    Journal of child and adolescent psychopharmacology
  • 2000
Modafinil may be a viable alternative to conventional stimulants for the treatment of adults with ADHD and scores on the DSM-IV ADHD Checklist were significantly improved over the placebo condition following treatment with both active medications.

Non-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder

Clinical guidelines for each of these agents, as well as their use in combination with stimulants in comorbid conditions, will be discussed.

Efficacy and Safety of Modafinil Film–Coated Tablets in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study

Intention-to-treat analysis (ITT) showed that compared with placebo, treatment with modafinil significantly improved the core symptoms of ADHD as shown by greater reductions in the ADHD-RS-IV School Version total scores from baseline to final visit.

A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression

Preliminary evidence indicates that modafinil may improve fatigue and excessive sleepiness associated with a variety of conditions and may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression.

Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.

Fatigue improved in both modafinil and placebo groups, and there were no differences between groups on changes in fatigue, symptoms, attention, working memory, or executive functioning.

New drugs for the treatment of attention-deficit/hyperactivity disorder

Atatoxetine, a selective noradrenergic re-uptake inhibitor, is the first non-stimulant compound to receive FDA approval for paediatric and adult ADHD.

Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.

Modafinil significantly improved symptoms of ADHD both at school and at home and was well tolerated by children and adolescents.